U.S. Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024

Description

U.S. Nuclear Medicine Market was valued at around USD 6.5 billion in 2023 and is projected to grow at a CAGR of 15.6% from 2024 to 2032. This growth is largely driven by advancements in radiopharmaceutical technology, rising disease prevalence, and the expanding role of personalized medicine. A key trend within this market is the increasing demand for radiopharmaceuticals, especially for oncology, cardiology, and neurology applications. The prevalence of cancer, cardiovascular conditions, and neurological disorders is prompting healthcare providers to utilize advanced diagnostic and therapeutic tools, leading to higher adoption of nuclear imaging techniques like PET and SPECT scans. Radiopharmaceutical production advancements are also enhancing isotope quality and availability, critical for the efficacy and safety of these imaging agents.

Innovations in synthesis and quality control processes are strengthening clinical applications, making radiopharmaceuticals more effective for targeted diagnoses and treatments. Segmented by product, the U.S. nuclear medicine market includes diagnostics and therapeutics. The diagnostics segment held a significant share, valued at around USD 4.5 billion in 2023. Growth in this segment is fueled by several factors, including an aging population, rising chronic disease rates, advancements in imaging technology, and a focus on early, accurate diagnostics. The trend towards personalized medicine also supports this growth, as diagnostics are increasingly tailored to patient-specific conditions.

When categorized by end use, the market includes hospitals, diagnostic centers, research institutions, and other facilities. Hospitals led the market in 2023, with anticipated growth reaching USD 15 billion by 2032. The demand for advanced diagnostic tools like PET and SPECT scans, which deliver detailed and early disease diagnoses, is prominent in hospital settings due to their specialized infrastructure and skilled staff, facilitating high adoption rates of nuclear medicine technologies. East North Central U.S. nuclear medicine market contributed USD 1 billion in revenue in 2023 and is forecasted to expand at a CAGR of 16% through 2032. This regional growth is driven by high rates of cancer and cardiovascular disease, boosting demand for diagnostic and therapeutic nuclear medicine procedures. The presence of leading medical institutions and research hubs has also fostered the adoption of nuclear imaging technologies, improving accessibility and supporting advancements in this field.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$6.5 Billion
Forecast Value	$24.7 Billion
CAGR	15.6%

Product Code: 11978

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of chronic diseases across the U.S.
  - 3.2.1.2 Rising technological advancements in nuclear medicine
  - 3.2.1.3 Rise in healthcare expenditure
  - 3.2.1.4 Favorable government initiatives
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of radiotherapy
  - 3.2.2.2 Short half-life of radiopharmaceuticals
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diagnostics
- 5.2.1 Single photon emission computed tomography (SPECT) isotopes
  - 5.2.1.1 TC-99 m
  - 5.2.1.2 I-123
  - 5.2.1.3 GA-67
  - 5.2.1.4 TL-201
  - 5.2.1.5 Other SPECT isotopes
- 5.2.2 Positron emission tomography (PET) isotopes
  - 5.2.2.1 F-18
  - 5.2.2.2 RB-82
  - 5.2.2.3 Other PET isotopes
5.3 Therapeutics
- 5.3.1 Beta emitters
  - 5.3.1.1 I-131
  - 5.3.1.2 Lu-177
  - 5.3.1.3 Y-90
  - 5.3.1.4 SM-153
  - 5.3.1.5 Re-186
  - 5.3.1.6 Other beta emitters
- 5.3.2 Brachytherapy isotopes
  - 5.3.2.1 Iridium-192
  - 5.3.2.2 Iodine-125
  - 5.3.2.3 Cesium-131
  - 5.3.2.4 Palladium-103
  - 5.3.2.5 Other brachytherapy isotopes
- 5.3.3 Alpha emitters
  - 5.3.3.1 RA-223
  - 5.3.3.2 Other alpha emitters

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Neurology
6.3 Cardiology
6.4 Oncology
6.5 Thyroid
6.6 Pulmonary
6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic centres
7.4 Research institutes
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Zone, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 East North Central
8.3 West South Central
8.4 South Atlantic
8.5 Northeast
8.6 East South Central
8.7 West North Central
8.8 Pacific Central
8.9 Mountain States

Chapter 9 Company Profiles

9.1 Actinium Pharmaceuticals
9.2 Best Medical International
9.3 Boston Scientific Corporation
9.4 Bracco
9.5 Cardinal Health
9.6 Curium Pharma
9.7 GE Healthcare
9.8 GT Medical Technologies
9.9 Iso-Tex Diagnostics
9.10 ITM Isotope Technologies
9.11 Jubilant Pharma
9.12 Lantheus
9.13 Novartis
9.14 RadioMedix
9.15 RLS Radiopharmacies
9.16 Siemens Healthineers
9.17 Sirtex
9.18 Sun Pharmaceutical Industries
9.19 Theragenics Corporation

U.S. Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032